WO2023208882A1 - Composition pharmaceutique de nilotinib - Google Patents

Composition pharmaceutique de nilotinib Download PDF

Info

Publication number
WO2023208882A1
WO2023208882A1 PCT/EP2023/060723 EP2023060723W WO2023208882A1 WO 2023208882 A1 WO2023208882 A1 WO 2023208882A1 EP 2023060723 W EP2023060723 W EP 2023060723W WO 2023208882 A1 WO2023208882 A1 WO 2023208882A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid composition
acid
sodium
solution
nilotinib
Prior art date
Application number
PCT/EP2023/060723
Other languages
English (en)
Inventor
Syed S. Kaiser KABIR
Syed Omar KABIR
Ganesh Vinayak Gat
Rambabu BOORUGU
A.H.M. Masbahur RAHMAN
Original Assignee
Renata Pharmaceuticals (Ireland) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renata Pharmaceuticals (Ireland) Limited filed Critical Renata Pharmaceuticals (Ireland) Limited
Publication of WO2023208882A1 publication Critical patent/WO2023208882A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the present invention relates to a field of an oral liquid pharmaceutical compositions in general, and in particular to an oral liquid pharmaceutical composition of nilotinib and a process for preparing the same.
  • Nilotinib is 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4- methyl-lH-imidazol-l-yl) -3-(trifluoromethyl)phenyl] benzamide.
  • a particularly useful salt of nilotinib is nilotinib hydrochloride monohydrate.
  • These therapeutic compounds have utility as inhibitors of the protein tyrosine kinase (TK) activity of Bcr-Abl. Examples of conditions that may be treated by such therapeutic compounds include, but are not limited to, chronic myeloid leukemia and gastrointestinal stromal tumors.
  • TasignaTM oral capsule has been developed for chronic myeloid leukemia and gastrointestinal stromal tumors.
  • Nilotinib is commercially available as 50mg oral capsule, lOOmg oral capsule, 150mg oral capsule and 200mg oral capsule.
  • Nilotinib is very slightly soluble drug in water and slightly soluble drug in alcohol, belonging to the BCS class IV, and its solubility in water is 0.2pg/ml.
  • the Nilotinib capsules developed by Novartis use micronized Nilotinib along with Poloxamer 188 as a solubilizer to increase the solubility of the drug.
  • Novartis further discloses, problem of nilotinib overdose in combination with alcohol.
  • the concentration of therapeutic compound in the pharmaceutical composition is present in an amount, e.g., in a therapeutically effective amount, which will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to one of ordinary skill in the art. Furthermore, it is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular recipient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the pharmaceutical compositions.
  • the therapeutic compound may be administered once, or may be divided into a number of smaller doses to be administered at varying intervals of time. Thus, an appropriate amount, e.g., an appropriate therapeutically effective amount, is known to one of ordinary skill in the art.
  • oral liquid compositions comprising nilotinib or its salt thereof, in aqueous solution form provide the desired stability profile.
  • the said composition is cost effective, safe and process of obtaining it is less complex.
  • the present inventors have also surprisingly found that aqueous oral nilotinib can be stored at room temperature and inhibit the formation of the impurity, while maintaining a functioning solution.
  • oral pharmaceutical composition comprising nilotinib that exhibits aqueous oral solution.
  • One aspect of the invention is an aqueous oral solution comprising (i) Nilotinib,
  • a cyclodextin comprising cyclodextrin, a derivative of cyclodextrin, or any combination thereof, and (iii) optionally one or more excipient, where the solution is stored at ambient temperature (e.g., 25° C.) and 60% relative humidity.
  • the solution is formulated such that it remains a solution during storage and the nilotinib does not precipitate out.
  • Yet another aspect is a method of dispensing to a patient an aqueous oral solution comprising (i) nilotinib, (ii) a cyclodextin comprising cyclodextrin, a derivative of cyclodextrin, or any combination thereof, and (iii) optionally one or more acid.
  • the present invention relates to an aqueous oral solution comprising nilotinib and one or more cyclodextin comprising cyclodextrin, a derivative of cyclodextrin, wherein the solution is free or substantially free (e.g.
  • v/v contains less than about 10% v/v, such as less than about 5% v/v, less than about 2.5% v/v, less than about 2% v/v, less than about 1.5% v/v, less than about 1% v/v, less than about 0.5% w/v, less than about 0.3% v/v, less than about 0.2% v/v, less than about 0.1% v/v, less than about 0.05% v/v, or less than about 0.01% v/v) of alcohol.
  • 10% v/v such as less than about 5% v/v, less than about 2.5% v/v, less than about 2% v/v, less than about 1.5% v/v, less than about 1% v/v, less than about 0.5% w/v, less than about 0.3% v/v, less than about 0.2% v/v, less than about 0.1% v/v, less than about 0.05% v/v, or less than about 0.01% v/v)
  • Yet another aspect is a method of dispensing to a patient an aqueous oral solution comprising (i) nilotinib, (ii) a cyclodextin comprising cyclodextrin, a derivative of cyclodextrin, or any combination thereof, (iii) optionally one or more polyol.
  • the liquid composition comprises about 10% (w/v) to about 50% (w/v) of polyol (also known as sugar alcohol), or about 15% (w/v) to about 50% (w/v) of polyol.
  • polyol also known as sugar alcohol
  • Exemplary polyols that can be used in the inventive compositions include sorbitol, xylitol, maltitol, glycerine, propylene glycol, erythritol and combinations thereof.
  • the liquid composition comprises about 15% (w/v) to about 40% (w/v) sorbitol or 15% (w/v) to about 25% (w/v) sorbitol, or about 16% (w/v) to about 26% (w/v) sorbitol or about 18% (w/v) to about 24% (w/v) sorbitol and in other embodiments, the liquid composition comprises about 21% (w/v) sorbitol. In other embodiments the liquid composition comprises about 15% (w/v) to about 40% (w/v) of a combination of sorbitol and maltitol.
  • the liquid composition comprises about 15% (w/v) to 25% (w/v) of maltitol and in other embodiments, the composition comprises about 20% (w/v) maltitol. In other embodiments the liquid composition comprises about 1% (w/v) to about 25% (w/v) of glycerine, and in other embodiments the liquid composition comprises about 5% (w/v) glycerine. In other embodiments the liquid composition comprises about 5% to about 50% propylene glycol (w/v).
  • the co- solvents are organic solvents such as propylene glycol, polyethylene glycol, and combinations thereof that are pharmaceutically acceptable based on the desired formulation.
  • the formulation contains from about 5% to about 50% by weight propylene glycol.
  • the solution may comprise a sweetener, such as sucralose, sucrose, or sodium saccharin.
  • a sweetener such as sucralose, sucrose, or sodium saccharin.
  • the solution comprises from about 0 to about 1% w/v sweetener.
  • the solution comprises from about 0.001 to about 1% w/v sucralose, such as about 0.025% w/v sucralose.
  • the sweetener of the liquid composition is an artificial sweetener (also known in the art as a “high intensity sweetener”).
  • artificial sweeteners include sucralose, acesulfame potassium, aspartame, and the saccharins.
  • the artificial sweetener is selected from sucralose and saccharin.
  • the sucralose is present at a concentration of about 0.35% (w/v); in other embodiments, the concentration of sucralose is from about 0.1% (w/v) to about 0.8% (w/v).
  • the concentration of saccharin is about 0.05% (w/v) to about 0.25% (w/v) or 0.2% (w/v) to about 0.8% (w/v) and in other embodiments, the concentration of saccharin is about 0.15% (w/v).
  • the solution comprises from about 0.05 to about 1.0% w/v of nilotinib, such as from about 0.1 to about 0.5% w/v of nilotinib, or from 0.1 to about 0.35% w/v of nilotinib.
  • the solution comprises about 0.33% w/v of nilotinib. In another embodiment, the solution comprises about 0.2% w/v of nilotinib.
  • the one or more acid include but are not limited to acetic acid, ascorbic acid, citric acid, fumaric acid, lauric acid, glacial, sorbic acid, malic acid, succinic acid, tartaric acid, phosphoric acid, hydrochloric acid, amino acid and mixtures thereof.
  • Organic acids which enhance the taste of the solution, are especially useful.
  • Citric acid for example, adds tartness that is a taste enhancer, and may play a role in overall stability of the solution.
  • Suitable amino acid include but are not limited to lysine, alanine, glutamic acid, tryptophan and mixture thereof.
  • the concentration of the acid in the solvent system is in the range of about 0.1% to about 5.0% or about 0.25% to about 3.0% or about 0.5% to about 2% or about 1%.
  • the one or more preservatives comprise Bronopol, Imidurea, Potassium Sorbate, Phenoxyethanol, Phenylmercuric Acetate, Butylparaben, Benzyl Alcohol, Phenylmercuric Borate, Chlorocresol, Benzethonium Chloride, Phenylethyl Alcohol, Benzalkonium Chloride, Methylparaben, Hexetidine, Chlorobutanol, Ethylparaben, Propylparaben, Sodium Benzoate, Potassium Benzoate, Sorbic Acid, Cresol, Propylparaben Sodium, Cetylpyridinium Chloride, Phenylmercuric Nitrate, Chloroxylenol, Propionic Acid, Phenol, Thimerosal, Sulfur Dioxide, Boric Acid, Edetic Acid, Sodium Propionate, Calcium
  • the one or more preservatives comprise methylparaben, propylparaben, or a combination thereof.
  • the oral solution may comprise methylparaben and propylparaben.
  • the oral solution may comprise methylparaben and propylparaben.
  • the solution includes an effective amount of preservatives (such as methylparaben, propylparaben, sodium benzoate, sodium methylparaben, or a combination thereof) to inhibit microbial contamination of the solution.
  • the solution includes from about 0.01 to about 4% (such as from about 0.05 to about 1% or from about 0.05 to about 0.5%) of preservatives, such as methylparaben, propylparaben, or a combination thereof.
  • the solution includes from about 0.1 to about 0.2% of preservatives, such as methylparaben, propylparaben, or a combination thereof.
  • the solution comprises one or more flavoring agents, such as, e.g., natural grape flavor.
  • suitable flavoring agents include but are not limited to, cotton candy, raspberry, strawberry, lemonlime, apple, mint, licorice, orange, lemon, grapefruit, caramel, vanilla, cherry, grape flavors, tutti-frutti, cherry flavors, combinations thereof, and the like.
  • the solution comprises from about 0.01 to about 2% w/v flavoring agent (e.g., natural grape flavor), such as about 1.0% w/v flavoring agent.
  • the stable oral liquid pharmaceutical compositions of the present application comprises of at least one solubilisers selected from the group of nonionic, anionic, cationic and zwitterionic surfactants or mixtures thereof.
  • Suitable non-limiting examples of the solubiliser(s) used in the compositions of the present application includes, but not limited to, polyethoxylated fatty acids like esters of lauric acid, oleic acid, and stearic acid, PEG-fatty acid diesters like PEG-20 dilaurate, PEG- fatty acid mono- and di-ester mixtures, alcohol-oil transesterification products like PEG-35 castor oil, Polyoxy 35 castor oil, polyoxyl 40 hydrogenated castor oil, etc., polyglycerized fatty acids like poly glyceryl oleate, etc., propylene glycol fatty acid esters like propylene glycol monolaurate etc, mixtures of propylene glycol esters-glycerol esters like oleic acid esters of propylene glycol and glycerol, etc., sterol and sterol derivatives like PEG-24 cholesterol ether etc, polyethylene glycol sorbitan fatty acid esters
  • Additional exemplary solubilisers include, but are not limited to: polyoxyethylene alkylethers; polyethylene glycol fatty acid esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; poly glycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides
  • Ionic surfactants include sodium oleate, sodium lauryl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, and sodium taurocholate; Gelucire® 44/14, etc.
  • the at least one solubilisers be present in the stable oral liquid pharmaceutical compositions disclosed herein in a variety of concentrations.
  • the stable oral liquid pharmaceutical compositions disclosed herein can comprise at least one solubilisers of at least 1% by weight, at least 2% by weight, at least 5% by weight, at least 10% by weight, at least 15% by weight, at least 20% by weight, or a percentage between any two of the above values, based on the total weight of the composition.
  • the nilotinib composition of present application comprises of at least one solubilisers in an amount of from about 1 % to about 20% by weight, or from about 2% to about 15% by weight, or from about 2% to about 10% by weight, or from about 3% to about 10% by weight, based on the total weight of the composition.
  • the pH of the aqueous oral solution ranges from about 2 to about 7. In another of any of the aqueous oral solutions described herein, the pH of the aqueous oral solution ranges from about 2.5 to about 4. For instance, the pH may be 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, or 3.5.
  • the stable oral liquid pharmaceutical compositions of the present application may comprises of at least one buffering agents.
  • buffering agents include, but are not limited to sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, aluminum hydroxide, aluminum hydroxide/sodium bicarbonate co precipitate, mixture of an amino acid and a buffer, a mixture of aluminum glycinate and a buffer, a mixture of an acid salt of an amino acid and a buffer, and a mixture of an alkali salt of an amino acid and a buffer.
  • Additional buffering agents include citric acid, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogenphosphate, dipotassium hydrogenphosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, and other calcium salts.
  • the solution may comprises anti-oxidant.
  • the anti-oxidant included in the formulations of the invention may further be selected from e.g., propyl gallate, lecithin, Vitamin E tocopherol, sesamin, sesamol, sesamolin, alpha tocopherol, ascorbic acid, ascorbyl palmitate, fumaric acid, malic acid, and sodium metabisulphite, disodium EDTA, and combinations of any of the foregoing.
  • Another aspect of the present invention is to provide an aqueous oral solution composition containing, while having a reduced bitter taste of the drug.
  • a further aspect of the present invention is to provide a syrup composition which is easy to take.
  • oral pharmaceutical composition comprising nilotinib that exhibits aqueous oral solution.
  • One aspect of the invention is an aqueous oral solution comprising (i) Nilotinib, (ii) cyclodextrin, and (iii) optionally one or more excipient, where the solution is stored at ambient temperature (e.g., 25° C.) and 60% relative humidity.
  • the solution is formulated such that it remains a solution during storage and the nilotinib does not precipitate out.
  • Yet another aspect is a method of dispensing to a patient an aqueous oral solution comprising (i) nilotinib, (ii) a cyclodextin comprising cyclodextrin, a derivative of cyclodextrin, or any combination thereof, and (iii) optionally one or more acid.
  • the present invention relates to an aqueous oral solution comprising nilotinib and one or more cyclodextrin, wherein the solution is free or substantially free (e.g. contains less than about 10% v/v, such as less than about 5% v/v, less than about 2.5% v/v, less than about 2% v/v, less than about 1.5% v/v, less than about 1% v/v, less than about 0.5% w/v, less than about 0.3% v/v, less than about 0.2% v/v, less than about 0.1% v/v, less than about 0.05% v/v, or less than about 0.01% v/v) of alcohol.
  • the solution is free or substantially free (e.g. contains less than about 10% v/v, such as less than about 5% v/v, less than about 2.5% v/v, less than about 2% v/v, less than about 1.5% v/v, less than about 1% v/v, less than
  • Yet another aspect is a method of dispensing to a patient an aqueous oral solution comprising (i) nilotinib, (ii) a cyclodextin comprising cyclodextrin, a derivative of cyclodextrin, or any combination thereof, (iii) optionally one or more polyol.
  • the liquid composition comprises about 10% (w/v) to about 50% (w/v) of polyol (also known as sugar alcohol), or about 15% (w/v) to about 50% (w/v) of polyol.
  • polyol also known as sugar alcohol
  • exemplary polyols that can be used in the inventive compositions include sorbitol, xylitol, maltitol, glycerine, propylene glycol, erythritol and combinations thereof.
  • the liquid composition comprises about 15% (w/v) to about 40% (w/v) sorbitol or 15% (w/v) to about 25% (w/v) sorbitol, or about 16% (w/v) to about 26% (w/v) sorbitol or about 18% (w/v) to about 24% (w/v) sorbitol and in other embodiments, the liquid composition comprises about 21% (w/v) sorbitol. In other embodiments the liquid composition comprises about 15% (w/v) to about 40% (w/v) of a combination of sorbitol and maltitol.
  • the liquid composition comprises about 15% (w/v) to 25% (w/v) of maltitol and in other embodiments, the composition comprises about 20% (w/v) maltitol. In other embodiments the liquid composition comprises about 1% (w/v) to about 25% (w/v) of glycerine, and in other embodiments the liquid composition comprises about 5% (w/v) glycerine. In other embodiments the liquid composition comprises about 5% to about 50% propylene glycol (w/v).
  • the co- solvents are organic solvents.
  • Organic solvent include but are not limited to propylene glycol, polyethylene glycol, and combinations thereof that are pharmaceutically acceptable based on the desired formulation.
  • the formulation contains from about 5% to about 50% by weight propylene glycol.
  • the solution may comprises a sweetener, such as sucralose, sucrose, or sodium saccharin.
  • a sweetener such as sucralose, sucrose, or sodium saccharin.
  • the solution comprises from about 0 to about 1% w/v sweetener.
  • the solution comprises from about 0.001 to about 1% w/v sucralose, such as about 0.025% w/v sucralose.
  • the sweetener of the liquid composition is an artificial sweetener (also known in the art as a “high intensity sweetener”).
  • artificial sweeteners include sucralose, acesulfame potassium, aspartame, and the saccharins.
  • the artificial sweetener is selected from sucralose and saccharin.
  • the sucralose is present at a concentration of about 0.35% (w/v); in other embodiments, the concentration of sucralose is from about 0.1% (w/v) to about 0.8% (w/v).
  • the concentration of saccharin is about 0.05% (w/v) to about 0.25% (w/v) or 0.2% (w/v) to about 0.8% (w/v) and in other embodiments, the concentration of saccharin is about 0.15% (w/v).
  • the solution comprises from about 0.05 to about 1.0% w/v of nilotinib, such as from about 0.1 to about 0.5% w/v of nilotinib, or from 0.1 to about 0.35% w/v of nilotinib. [0052] In one aspect of any of the aqueous oral solutions described herein, the solution comprises about 0.33% w/v of nilotinib. In another embodiment, the solution comprises about 0.2% w/v of nilotinib.
  • the one or more acid include but are not limited to acetic acid, ascorbic acid, citric acid, fumaric acid, lauric acid, glacial, sorbic acid, malic acid, succinic acid, tartaric acid, phosphoric acid, hydrochloric acid, amino acid and mixtures thereof.
  • Organic acids which enhance the taste of the solution, are especially useful.
  • Citric acid for example, adds tartness that is a taste enhancer, and may play a role in overall stability of the solution.
  • Suitable amino acid include but are not limited to lysine, alanine, glutamic acid, tryptophan and mixture thereof.
  • the concentration of the acid in the solvent system is in the range of about 0.1% to about 5.0% or about 0.25% to about 3.0% or about 0.5% to about 2% or about 1%.
  • the one or more preservatives comprise Bronopol, Imidurea, Potassium Sorbate, Phenoxyethanol, Phenylmercuric Acetate, Butylparaben, Benzyl Alcohol, Phenylmercuric Borate, Chlorocresol, Benzethonium Chloride, Phenylethyl Alcohol, Benzalkonium Chloride, Methylparaben, Hexetidine, Chlorobutanol, Ethylparaben, Propylparaben, Sodium Benzoate, Potassium Benzoate, Sorbic Acid, Cresol, Propylparaben Sodium, Cetylpyridinium Chloride, Phenylmercuric Nitrate, Chloroxylenol, Propionic Acid, Phenol, Thimerosal, Sulfur Dioxide, Boric Acid, Edetic Acid, Sodium Propionate, Calcium
  • the one or more preservatives comprise methylparaben, propylparaben, or a combination thereof.
  • the oral solution may comprise methylparaben and propylparaben.
  • the oral solution may comprise methylparaben and propylparaben.
  • the solution includes an effective amount of preservatives (such as methylparaben, propylparaben, sodium benzoate, sodium methylparaben, or a combination thereof) to inhibit microbial contamination of the solution.
  • preservatives such as methylparaben, propylparaben, sodium benzoate, sodium methylparaben, or a combination thereof
  • the solution includes from about 0.01 to about 4% (such as from about 0.05 to about 1% or from about 0.05 to about 0.5%) of preservatives, such as methylparaben, propylparaben, or a combination thereof.
  • the solution includes from about 0.1 to about 0.2% of preservatives, such as methylparaben, propylparaben, or a combination thereof.
  • the solution comprises one or more flavoring agents.
  • suitable flavoring agents include but, are not limited to, cotton candy, raspberry, strawberry, lemon-lime, apple, mint, licorice, orange, lemon, grapefruit, caramel, vanilla, cherry, grape flavors, tutti-fruti, cherry flavors, combinations thereof; and the like.
  • the solution comprises from about 0.01 to about 2% w/v flavoring agent (e.g., natural grape flavor), such as about 1.0% w/v flavoring agent.
  • the stable oral liquid pharmaceutical compositions of the present application comprises of at least one solubilisers selected from the group of nonionic, anionic, cationic and zwitterionic surfactants or mixtures thereof.
  • Suitable non-limiting examples of the solubiliser(s) used in the compositions of the present application includes, but not limited to, polyethoxylated fatty acids like esters of lauric acid, oleic acid, and stearic acid, PEG-fatty acid diesters like PEG-20 dilaurate, PEG- fatty acid mono- and di-ester mixtures, alcohol-oil transesterification products like PEG-35 castor oil, Polyoxy 35 castor oil, polyoxyl 40 hydrogenated castor oil, etc., polyglycerized fatty acids like poly glyceryl oleate, etc., propylene glycol fatty acid esters like propylene glycol monolaurate etc, mixtures of propylene glycol esters-glycerol esters like oleic acid esters of propylene glycol and glycerol, etc., sterol and sterol derivatives like PEG-24 cholesterol ether etc, polyethylene glycol sorbitan fatty acid esters
  • Additional exemplary solubilisers include, but are not limited to: polyoxyethylene alkylethers; polyethylene glycol fatty acid esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; poly glycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides
  • Ionic surfactants include sodium oleate, sodium lauryl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, and sodium taurocholate; Gelucire® 44/14, etc.
  • the at least one solubilisers be present in the stable oral liquid pharmaceutical compositions disclosed herein in a variety of concentrations.
  • the stable oral liquid pharmaceutical compositions disclosed herein can comprise at least one solubilisers of at least 1% by weight, at least 2% by weight, at least 5% by weight, at least 10% by weight, at least 15% by weight, at least 20% by weight, or a percentage between any two of the above values, based on the total weight of the composition.
  • the nilotinib composition of present application comprises of at least one solubilisers in an amount of from about 1 % to about 20% by weight, or from about 2% to about 15% by weight, or from about 2% to about 10% by weight, or from about 3% to about 10% by weight, based on the total weight of the composition.
  • the pH of the aqueous oral solution ranges from about 2 to about 7. In another of any of the aqueous oral solutions described herein, the pH of the aqueous oral solution ranges from about 2.5 to about 4. For instance, the pH may be 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, or 3.5.
  • the stable oral liquid pharmaceutical compositions of the present application may comprises of at least one buffering agents.
  • buffering agents include, but are not limited to sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, aluminum hydroxide, aluminum hydroxide/sodium bicarbonate co precipitate, mixture of an amino acid and a buffer, a mixture of aluminum glycinate and a buffer, a mixture of an acid salt of an amino acid and a buffer, and a mixture of an alkali salt of an amino acid and a buffer.
  • Additional buffering agents include citric acid, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogenphosphate, dipotassium hydrogenphosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, and other calcium salts.
  • the solution may comprises anti-oxidant.
  • the anti-oxidant included in the formulations of the invention may further be selected from e.g., propyl gallate, lecithin, Vitamin E tocopherol, sesamin, sesamol, sesamolin, alpha tocopherol, ascorbic acid, ascorbyl palmitate, fumaric acid, malic acid, and sodium metabisulphite, disodium EDTA, and combinations of any of the foregoing.
  • Another aspect of the present invention is to provide an aqueous oral solution composition containing, while having a reduced bitter taste of the drug.
  • Nilotinib as used herein encompasses base form as well as its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates.
  • the solid state form of nilotinib used in the composition of the present application is not critical.
  • nilotinib can be amorphous or crystalline.
  • salts as used herein includes those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, which are well known in the art.
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the pharmaceutically active substance, having a freebase function, with a suitable organic acid or inorganic acid.
  • an “effective amount” or a “therapeutically effective amount” of a drug refers to a non-toxic, but sufficient amount of the drug, to achieve therapeutic results in treating a condition for which the drug is known to be effective.
  • an effective amount is an amount of nilotinib which is sufficient to treat leukemia in a patient in need thereof.
  • the term "nilotinib” or a pharmaceutically acceptable salt thereof refers to nilotinib free base or any pharmaceutically acceptable salt of nilotinib, the pharmaceutical composition of the present invention may include nilotinib in amounts ranging from about 0.05 % w/v to about 20 % w/v of the composition.
  • liquid composition refers to a liquid composition that is ingested with or without further mixing with aqueous or suitable media before oral administration.
  • stable composition(s) refers to a composition that does not show any precipitation in Simulated Gastric Fluid (SGF) at pH 1.2, temperature of 37° C.+0.5 0 C. and under stirring at a speed of 50 rpm at least for 60 minutes.
  • stable composition(s) refers to a composition which upon subjected to stability evaluation at 40° C. and 75% RH (relative humidity) or 25° C. and 60% RH (relative humidity), is substantially free of impurities, or comprises not more than 5% impurities, or comprises impurities levels which are acceptable by regulatory bodies such as US FDA.
  • Cyclodextrins are compounds made up of sugar molecules bound together in a ring and are composed of 5 or more a-D-glucopyranoside units linked 1— >4. Cyclodextrins are produced from starch by means of enzymatic conversion. Three major non-substituted cyclodextrins are known, containing each a different number of glucose monomers ranging from six to eight in a ring, creating a conical shape. The so-called a-cyclodextrin is a sixmembered sugar ring molecule, P-cyclodextrin is a seven- membered sugar ring molecule and y-cyclodextrin is an eight-membered sugar ring molecule.
  • Suitable solubility enhancers include, without limitation, are beta cyclodextrin, hydroxyl beta cyclodextrin, betadex sulfobutyl ether cyclodextrin, methyl beta cyclodextrin, 2,6- dimethyl betacyclodextrin, hydroxyethyl betacyclodextrin, a-cyclodextrin, y-cyclodextrin.
  • flavoring agent is intended to mean a compound used to impart a pleasant flavor and often odor to a pharmaceutical preparation.
  • exemplary flavoring agents include synthetic flavor oils and flavoring aromatics and/or natural oils, extracts from plants, leaves, flowers, fruits and so forth and combinations thereof. These may also include cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leave oil, oil of nutmeg, oil of sage, oil of bitter almonds and cassia oil.
  • flavoring agents include vanilla, citrus oil, including lemon, orange, grape (e.g., natural grape), lime and grapefruit, and fruit essences, including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth.
  • the amount of flavoring agent may depend on a number of factors, including the organoleptic effect desired.
  • the inventive composition also comprises a sweetener.
  • Various sweeteners are contemplated, including but not limited to simple sugars such as sucrose, dextrose, fructose, maltose, and the like.
  • the inventive composition is “low calorie” or “light”, “sugar-free”, or “calorie-free.”
  • the sweetener in the inventive compositions may be a so-called “artificial sweetener” (also known as “high-intensity sweetener”), such as sucralose, acesulfame potassium, saccharin, and aspartame, or any combination thereof.
  • artificial sweeteners is desirable for adding sweetness without the addition of calories.
  • the polyol in the inventive composition may also provide some sweetening and the lower calorie content of polyols, and lower glycemic index (compared to simple sugars) make the inventive compositions suitable for low calorie diets. Additionally, the inventive compositions that are low calorie and/or low glycemic index would be suitable for diabetic patients.
  • sucgar-free means that a product contains no amount of, or only trivial or “physiologically inconsequential” amounts of sugars.
  • sucgar free means less than 0.5 g of sugars per serving.
  • Calorie free means fewer than 5 calories per serving. Examples of synonyms for “free” include “without,” “no” and “zero.” Those products sweetened only with artificial sweeteners and/or sugar alcohols (and containing no other sugars) can be classified as “sugar-free.”
  • low calorie is understood to mean 40 calories or less per reference amount.
  • additives conventionally used in pharmaceutical compositions can be included, and these additives are well known in the art.
  • Such additives include pharmaceutically acceptable detackifiers, anti-foaming agents, chelating agents, viscomodulators, tonicifiers, flavorants, colorants odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.
  • the amounts of such additives can be readily determined by one skilled in the art, according to the particular properties desired, keeping in mind the possibility that any such additives should preferably not negatively impact the stability of the final formulation.
  • Suitable coloring agents include red, black, and yellow iron oxides and FD&C dyes such as FD&C Blue No. 2, FD&C Red No. 40, and the like.
  • Suitable taste-masking agents include sodium bicarbonate, ion-exchange resins, cyclodextrin inclusion compounds, adsorbates, and the like.
  • excipients may perform more than one function and are therefore characterized as having different uses depending on the particular application. While the use of an excipient in the context of a particular formulation may determine the function of the excipient, the inclusion of any particular excipient into any one or more categories as set forth above is not meant to limit the function of that excipient.
  • Step-1 Propylene glycol and Nilotinib Hydrochloride Monohydrate is taken into a beaker and mixed using a stirrer until a clear solution is obtained.
  • Step-2 Purified water is taken in another breaker and Citric acid anhydrous is added and mixed, using a stirrer. Further to it, Sulfobutylether beta cyclodextrin is added with mixing until a clear solution was obtained.
  • Step-3 Step-2 solution is added to step-1 with mixing.
  • Step-4 Methylparaben sodium, propylparaben sodium, tutti frutti and liquid maltitol are sequentially added into purified water and mixed using a stirrer until a clear solution is obtained.
  • Step-5 Step-4 solution is added to step-3 and mixed using a stirrer.
  • Step-6 The volume of the Step 5 solution was adjusted using purified water up to 100%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique liquide orale de nilotinib et son procédé de préparation, ladite composition pharmaceutique liquide orale comprenant une quantité thérapeutiquement efficace de nilotinib et des adjuvants pharmaceutiquement acceptables, et la composition étant une solution aqueuse.
PCT/EP2023/060723 2022-04-25 2023-04-25 Composition pharmaceutique de nilotinib WO2023208882A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263334357P 2022-04-25 2022-04-25
US63/334,357 2022-04-25

Publications (1)

Publication Number Publication Date
WO2023208882A1 true WO2023208882A1 (fr) 2023-11-02

Family

ID=86316288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/060723 WO2023208882A1 (fr) 2022-04-25 2023-04-25 Composition pharmaceutique de nilotinib

Country Status (1)

Country Link
WO (1) WO2023208882A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160074337A1 (en) * 2011-08-17 2016-03-17 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
WO2016097011A1 (fr) * 2014-12-19 2016-06-23 Synthon B.V. Composition pharmaceutique comprenant de l'agomélatine amorphe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160074337A1 (en) * 2011-08-17 2016-03-17 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
WO2016097011A1 (fr) * 2014-12-19 2016-06-23 Synthon B.V. Composition pharmaceutique comprenant de l'agomélatine amorphe

Similar Documents

Publication Publication Date Title
US7125564B2 (en) Water soluble and palatable complexes
HU230456B1 (hu) Aripiprazol orális oldatai
EP2866802B1 (fr) Compositions liquides de racécadotril
KR101856283B1 (ko) 경구 투여용 용액
KR101490721B1 (ko) 감칠맛을 가진 디페리프론용 액상 제제
JP2021523202A (ja) 経口溶液製剤
CN109692153B (zh) 一种富马酸卢帕他定的水溶液制剂
JP3805646B2 (ja) 医薬液剤
JP6410814B2 (ja) フェキソフェナジンを含む経口投与用液体医薬組成物
US20060198856A1 (en) Ibuprofen suspension stabilized with docusate sodium
WO2023208882A1 (fr) Composition pharmaceutique de nilotinib
KR100675081B1 (ko) 아세틸시스테인 함유 경구용 제제
EP2908859B1 (fr) Formulations d'aripiprazole
US20070087981A1 (en) Water Soluble and Palatable Complexes
WO2020121277A1 (fr) Bâtonnets de diclofénac prêts à l'emploi
KR20200111138A (ko) 용해성 및 안정성이 향상된 덱시부프로펜 시럽제제
JP4514398B2 (ja) 内服用医薬組成物
KR20150127483A (ko) 몬테루카스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 안정성이 개선된 액상 제제 및 이의 제조방법
US20060100271A1 (en) Stabilized aqueous ranitidine compositions
US20040039036A1 (en) Water-soluble liquid internal medicine
KR20190093999A (ko) 용해성 및 안정성이 향상된 덱시부프로펜 시럽제제
WO2024116198A1 (fr) Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable
AU2773892A (en) Trimethoprim oral liquid
JP5298526B2 (ja) 内服用組成物
JP2007008852A (ja) プラバスタチンを含有する水性製剤の安定化方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23721419

Country of ref document: EP

Kind code of ref document: A1